Patients with acute promyelocytic leukemia often develop bleeding diatheses during treatment. In seven patients who had this disease, the plasma level of alpha-2-plasmin inhibitor was the best predictor of severity of coagulopathy and bleeding. Clinical bleeding occurred when alpha-2-plasmin inhibitor levels measured less than 30% of normal levels. Patients with acute promyelocytic leukemia who had acquired deficiencies of alpha-2-plasmin inhibitor were considered to have deficits similar to those in persons congenitally deficient in alpha-2-plasmin inhibitor, and were assumed to be at increased risk for bleeding. Treatment with the fibrinolytic inhibitor, epsilon-aminocaproic acid, along with heparin resulted in prompt cessation of bleeding, reversal of laboratory evidence of fibrinolysis. and a decreased need for blood product support. The only thrombotic complicationthrombosis around a central venous catheter-resolved when treatment with epsilon-aminocaproic acid was discontinued. Epsilon-aminocaproic acid is a safe and effective therapy for those patients with acute promyelocytic leukemia who develop coagulopathy associated with low levels of alpha-2-plasmin inhibitor.
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THERAPY FOR acute promyelocytic leukemia (acute nonlymphocytic leukemia MJ of the French-American-British classification (I» presents special problems because of the coagulopathy that often accompanies the disease (2-4). The administration of heparin during induction chemotherapy allows patients to achieve remission with fewer bleeding complications (5-7). However, many patients with acute promyelocytic leukemia still develop major bleeding problems, and death from intracranial hemorrhage is not uncommon (8) .
The defibrination that occurs in patients with acute promyelocytic leukemia is caused by activation of the fibrinolytic system as well as intravascular coagulation (9) (10) (11) (12) (13) . The physiologic fibrinolytic response, initiated with the formation of fibrin (14) , may be exacerbated in patients with acute promyelocytic leukemia by the release of proteases from leukemic promyelocytes at cell lysis. Leukemic promyelocytes contain plasminogen activators (IS, 16) and enzymes, such as leukocyte elastase, that may inactivate inhibitors of fibrinolysis or degrade fibrinogen directly (17) . Although the diagnosis of a primarily fibrinolytic state is difficult (18) , recent evidence suggests that depletion of the fast-acting plasmin inhibitor of plasma (alpha-2-antiplasmin, or alpha-2-plasmin inhibitor) is a specific marker for systemic fibrinolysis (19, 20) . Persons who have congenital deficiencies in this inhibitor have severe, lifelong bleeding tendencies that are alleviated by treatment with the fibrinolytic inhibitor, tranexamic acid (21) (22) (23) (24) (25) . Results of several studies have shown low levels of alpha-2-plasmin inhibitor in patients with acute promyelocytic leukemia (10, 11, (26) (27) (28) . This inhibitor has an accelerated turnover in these patients (26) that resembles that found in patients treated with streptokinase (20) . Because we were not satisfied with the clinical outcomes with standard heparin treatment, we began to monitor alpha-2-plasmin inhibitor levels in patients with acute promyelocytic leukemia. We used a low level of alpha-2-plasmin inhibitor as an indication for addition of the antifibrinolytic drug, epsilon-aminocaproic acid, to heparin in the regimen given to such patients. This strategy worked well, and we suggest a role for epsilon-aminocaproic acid in a properly chosen and monitored subgroup of patients receiving heparin for acute promyelocytic leukemia.
Methods and Protocols
We detennined prothrombin times (nonnal range, 10.5 to 12.5 seconds) and activated partial thromboplastin times (normal range, 22 to 32 seconds) with commercial reagents on an automated instrument (MLA-700; Scientific Products, McGaw Park, Illinois). Fibrinogen concentrations were detennined by a clotting time assay (American Dade, Miami, Florida), and fibrin/fibrinogen degradation products, by a latex bead immunoassay (Dade); normal ranges were 150 to 350 mg/dL (4 to 10 p.mol/L) for fibrinogen and less than 8 p.g/mL for fibrin/fibrinogen degradation products. Alpha-2-plasmin inhibitor levels were determined by measuring inhibition (by diluted plasma) of plasmin turnover of a fluorogenic substrate (Dade Protopath). The nonnal range was 79% to 118%, as obtained by standard plasma pool. The coefficient of variation of the assay was 5% for samples with values in the nonnal range and 8% for samples with values measuring less than 50% of nonnal activity. Concentrations of antithrombin III (normal range, 90% to 130% of standard) and plasminogen (nonnal range, 75% to 130% of standard) were determined using automated chromogenic substrate-based assays (ACA; E.I. DuPont de Nemours Co., Wilmington, Delaware). In some samples, levels of antithrombin III and plasminogen were determined by using a manual fluorogenic substrate-based technique (Dade Protopath).
STANDARD TREATMENT Acute promyelocytic leukemia was diagnosed by bone marrow aspiration and biopsy according to the French-AmericanBritish criteria (I). We inserted a central venous catheter in six patients and a double-lumen Raaf catheter in one patient. Combination chemotherapy consisted of daunorubicin, 60 mg/m2 body surface area given intravenously on days I through 3; cytarabine, 200 mg/m2, given daily by continuous intravenous infusion or intravenous bolus on days I through 5; and 6-thioguanine, 100 mg/m2, given orally every 12 hours on days I 873 .. From the Section of Hematology, Departments of Medicine, Human Oncology, and Physiological Chemistry, University of Wisconsin; Madison, Wisconsin. levels of 20% of normal, which is the lowest level the assay can measure. Three of the four patients with nadir levels less than 30% of normal had significant bleeding. No patient had bleeding with an alpha-2-plasmin inhibitor level of greater than 30% of normal. Antithrombin III levels changed very little during induction chemotherapy and remained normal throughout treatment, except for isolated low values in two patients. through 5. Packed erythrocytes and platelet concentrates were infused to maintain hemoglobin concentrations of more than 10 g/dL and platelet counts of more than 20 OOO/IJ.L, respectively. Monitoring for infections and administration of treatment with combination broad-spectrum antibiotics were carried out according to protocols used at the University of Wisconsin Clinical Science Center (29) . Heparin therapy began with an intravenous bolus injection of 3000 to 5000 U that was followed by continuous infusion of 500 to 750 U/h. No attempt was made to prolong the activated partial thromboplastin time. Heparin therapy continued until no laboratory evidence of fibrinogen consumption could be found. In patients with prothrombin times of more than 15 seconds, fibrinogen levels of less than 100 mg/dL (2.7 IJ.mol/L), or both, fresh frozen plasma and cryoprecipitate were infused in quantities sufficient to correct these abnormalities.
EPSILON-AMINOCAPROIC ACID TREATMENT
Patients whose alpha-2-plasmin inhibitor levels dropped to below 40% of normal were given epsilon-aminocaproic acid in addition to heparin. One patient received the drug orally at a dosage of 1 g/2 h. The other four patients received the drug by continuous intravenous infusion at a dosage of 1 g/h after an initial intravenous bolus injection of 3 to 4 g. Epsilon-aminocaproic acid treatment continued until alpha-2-plasmin inhibitor levels rose above 40% of normal and leukemic promyelocytes could no longer be found in samples of bone marrow.
Results

COAGULATION STUDIES
The changes in coagulation variables that occurred during the first 10 days after the initiation of chemotherapy in seven consecutive patients with acute promyelocytic leukemia are shown in Figure 1 . Fibrinogen levels decreased significantly in five patients. including all three who had significant bleeding. However, the nadir levels were not extremely low; only one patient achieved a level of less than 100 mg/dL. Plasminogen and alpha-2-plasmin inhibitor levels fell in every patient whose levels were measured before treatment and reached subnormal levels in every patient. The decreases in alpha-2-plasmin inhibitor levels were most striking; three patients had nadir 874
December 1986 . Annals of Internal Medicine. Volume 105 . Nt CLINICAL OUTCOME Three patients had low alpha-2-plasmin inhibitor levels and significant bleeding (gross hematuria, oozing from venipuncture sites, mucosal bleeding, or intracranial bleeding). One of these patients received orally administered epsilon-aminocaproic acid and died of intracranial bleeding 48 hours after the start of induction chemotherapy. At autopsy, two large intracranial chloromas were found. Two other patients, whose clinical courses are charted in Figure 2 , received continuous intravenous infusions of epsilon-aminocaproic acid; bleeding stopped within 24 hours of the initiation of this treatment. An additional two patients were treated with epsilon-aminocaproic acid when their plasma alpha-2-plasmin inhibitor activity levels were found to measure below 40% of normal; neither of these patients had any bleeding. Two patients had no bleeding, and additional measurements of alpha-2-plasmin inhibitor levels showed them to be consistently greater than 40% of normal. Epsilon-aminocaproic acid was not given to these patients and no bleeding complications occurred. In all four patients treated with intravenous epsilon-aminocaproic acid, fibrinogen levels began to increase and titers of fibrin/fibrinogen degradation products began to decrease within 24 hours of initiation of the treatment. Plasminogen and alpha-2-plasmin inhibitor levels, however, remained low for 3 to 10 days more. No patient developed bacteremia during the administration of this treatment. One patient had symptomber 6 matic subclavian vein thrombosis at the site of a Raaf catheter that resolved quickly when epsilon-aminocaproic acid therapy was stopped and heparin therapy was continued. No other evidence of thrombosis was seen in the patients receiving epsilon-aminocaproic acid. The patient who died had no evidence of thrombosis at autopsy. Five patients, including four who had received epsilonaminocaproic acid treatment, achieved complete remission after one or two cycles of chemotherapy, one patient died during induction chemotherapy as described, and one patient had persistent leukemia.~~ iscussion Bleeding in patients with acute promyelocytic leukemia remains a vexing problem despite the routine use of heparin infusions. Results of this study and others (9-13, 15,26) suggest that a major cause of consumptive coagulopathy in patients with acute promyelocytic leukemia is activation of the fibrinolytic system, which results in rapid dissolution of clots before permanent hemostasis can be achieved. Every patient in this series had depletion of alpha-2-plasmin inhibitor at some point during the course of his or her disease. Levels of alpha-2-plasmin inhibitor of less than 30% of normal were associated with depletion of fibrinogen and generation of high titers of fibrin/fibrinogen degradation products. Three of four patients with alpha-2-plasmin inhibitor levels of less than 30% of normal had clinically apparent bleeding, whereas none of the three patients with alpha-2-plasmin inhibitor levels of greater than 30% had symptoms of bleeding. Levels of antithrombin III, which is consumed when thrombin and several other proteolytic clotting factors are generated (30) , were normal in our patients-a finding that has been reported previously in patients with acute promyelocytic leukemia (10, 31) . No evidence therefore existed for large-scale activation of procoagulant enzymes. Many patients reported to have had clinical and laboratory evidence of fibrinolysis, including those with acute promyelocytic leukemia and patients with low levels of alpha-2-plasmin inhibitor, have been treated effectively with antifibrinolytic agents (10, (32) (33) (34) (35) . In each patient in the present series, with the exception of one patient with intracranial leukemic masses who had received a low dosage of oral epsilon-aminocaproic acid, clinical and laboratory evidence of coagulopathy showed improvement within 24 hours after epsilon-aminocaproic acid treatment had begun. Depletion of alpha-2-plasmin inhibitor could be caused by the release of high levels of plasminogen activators from leukemic promyelocytes, which would lead to the subsequent generation of plasmin (15), or the release of leukocyte elastase, leading to the subsequent inactivation of alpha-2-plasmin inhibitor (17) . Regardless of the mechanism of depletion, however, a low plasma level of alpha-2-plasmin inhibitor in a patient with acute promyelocytic leukemia appears to be a risk factor for bleeding and justifies treatment with an antifibrinolytic drug. Observations based on patients congenitally deficient in alpha-2-plasmin inhibitor provide an additional rationale for this approach. Such patients have severe, lifelong bleeding tendencies that re- Bleeding was associated with alpha-2-plasmin inhibitor levels of less than 30% of normal in both patients. Days on which daunorubicin (dauno). cytarabine (Ara C). 6-thioguanine (6TG), low-dose cytarabine (/.0. Ara C). epsilon-aminocaproic acid (EACA). and heparin were given are indicated by bars at top of figure; arrows indicate days on which cryoprecipitate and fresh frozen plasma were given. Plasma concentrations of antithrombin III (A Till). alpha-2-plasmin inhibitor (a2 PI) and plasminogen (Pg) are indicated by crosses, triangles. and closed circles. respectively. and are given as percentage of normal. Plasma fibrinogen (Fg) concentrations (open circles) are given in mg/dL. Note that in panel B. the second course of chemotherapy was not accompanied by a drop in alpha-2-plasmin inhibitor titer; the patient had no bleeding, and epsilon-aminocaproic acid was not given.
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spond well to antifibrinolytic therapy (21) (22) (23) (24) (25) . Because alpha-2-plasmin inhibitor deficiency appears to correlate with clinical bleeding in patients with acute promyelocytic leukemia, serial alpha-2-plasmin inhibitor measurements can be used both to decide when antifibrinolytic therapy should be initiated and to monitor the
